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Long‑term surgical outcomes 
of primary retropupillary iris claw 
intraocular lens implantation 
for the treatment of intraocular 
lens dislocation
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We aimed to investigate the efficacy and safety of primary retropupillary iris claw intraocular lens 
(R‑IOL) implantation in patients with complete intraocular lens (IOL) dislocation. In this single‑
center retrospective case series, we reviewed the medical records of patients who underwent R‑IOL 
implantation surgery with pars plana vitrectomy for the treatment of IOL dislocation between 
September 2014 and July 2019. The primary outcome was change in visual acuity (VA) up to 24 months 
postoperatively. The secondary outcomes included changes in intraocular pressure (IOP), refractive 
errors, and endothelial cell count (ECC) over the same period. Data of 103 eyes (98 patients) were 
analyzed. The mean uncorrected VA was significantly improved at one month postoperatively (− 0.69 
logMAR, P < 0.001), compared to the preoperative value. IOP (− 2.3 mmHg, P = 0.008) and ECC 
(− 333.4 cells/mm2, P = 0.027) significantly decreased one month post‑surgery and remained stable 
thereafter. Postoperative mean spherical equivalents were similar to the prediction error throughout 
the follow‑up period. IOP elevation (n = 8, 7.8%), cystoid macular edema (n = 4, 3.9%), and dislocation 
of the R‑IOL (n = 10, 9.7%) were managed successfully. Overall, primary R‑IOL implantation with pars 
plana vitrectomy is effective and safe for correcting IOL dislocation due to various causes.
The widespread use of phacoemulsification, which strongly increases the proficiency of cataract operations, has 
steadily increased over the past 32  years1. Consequently, the incidence of intraocular lens (IOL) dislocation has 
increased with the increasing number of cataract surgeries that were performed. Therefore, the treatment for 
IOL dislocation is an emerging surgical dilemma and may impose a relatively large public health care burden in 
the future. In particular, complete IOL dislocation may predispose patients to serious retinal complications, such 
as vitreous hemorrhage and retinal  detachment2. In general, surgical management of complete IOL dislocation 
involves either pars plana vitrectomy and removal of the dislocated IOL, followed by secondary IOL implantation 
at the surgeon’s discretion, or re-fixation of the dislocated IOL without IOL removal.
Many clinicians have tried to develop an effective secondary IOL implantation technique that would yield 
the best visual outcome with minimal complications. Conventional secondary IOL implantation via scleral 
sutures has been the treatment of choice, as the position of the scleral-fixated IOL (SF-IOL) is ideal with respect 
to the anatomy of the eye. However, this technique requires the use of sutures and sufficient operator experience, 
and has a relatively long operation  time3. Secondary IOL scleral fixation may lead to other severe intraocu-
lar complications, such as vitreous hemorrhage, retinal detachment, choroidal detachment, and suture-related 
 complications4. An alternative procedure, secondary IOL implantation of anterior chamber IOLs, was popular-
ized in the 1980s due to its simplicity and efficacy. However, a high risk of developing postoperative secondary 
glaucoma, uveitis, and endothelial cell decompensation has been reported in cases of anterior chamber  IOL5 
with a particularly inflexible closed-loop  design6.
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Recently, the retropupillary iris claw intraocular lens (R-IOL) has emerged as a viable option for secondary 
IOL implantation. In the 1980s, Amar first proposed the fixation of an iris claw lens at the posterior surface of 
the  iris7. This R-IOL implantation technique gained popularity after Mohr et al. reported the 1-year clinical 
outcomes for this technique in  20028. Structurally, R-IOL provides better stability and lower risks of IOL tilt or 
dislocation than iris- or scleral-sutured lenses. In addition, the absence of sutures for IOL scleral fixation lowers 
the risk for suture-related complications, such as conjunctival erosion, scleromalacia, and  endophthalmitis9,10. 
Many previous studies have shown that secondary R-IOL is a safe and efficacious technique for correcting vari-
ous aphakic conditions  with11–17 or without IOL  dislocation3,18. However, the long-term safety and efficacy of 
simultaneous primary R-IOL implantation and vitrectomy in patients with complete IOL dislocation have not 
been previously assessed.
Herein, we present our surgical method for correcting IOL dislocation using R-IOL and investigate the long-
term efficacy and safety of primary R-IOL implantation in patients with complete IOL dislocation.
Materials and methods
This was a single-center, retrospective case series study. We reviewed the records and operative reports of all 
patients who underwent R-IOL implantation (performed by a single surgeon—M. Kim) at the Department of 
Ophthalmology, Gangnam Severance Hospital, between September 2014 and July 2019. The study was conducted 
in accordance with the Declaration of Helsinki, and the protocol was approved by the Institutional Review Board 
at Gangnam Severance Hospital (IRB approval number: 3-2020-0213). The requirement for informed patient 
consent was waived because the data were anonymized before the analysis.
We have selectively included cases of IOL dislocation involving total dislocation of the in-the-bag IOL into 
the posterior segment or cases of recurrent complete dislocation of the SF-IOL, which were treated by the 
removal of the dislocated IOL followed by R-IOL implantation. Cases in which dislocated IOLs were rescued 
and repositioned were not included in this study. We included all patients in the analysis, including those with 
various complicated retinal pathologies.
Preoperative examination. All past medical history and preoperative ophthalmologic data for each 
patient were reviewed. Preoperative uncorrected visual acuity (VA) and best-corrected VA (BCVA) obtained 
using the Snellen vision chart, which were converted to logMAR values for statistical analysis, were obtained. 
Preoperative intraocular pressure (IOP) was measured using a non-contact tonometer. Preoperative refrac-
tive data were obtained using an auto kerato-refractometer (KR-1, Topcon Medical Systems, Inc.; Oakland, NJ, 
USA); spherical equivalent (SE) and corneal astigmatism were also calculated. The auto KR values were used as 
the starting point to perform manifest refraction, and the best subjective correction for a distance of 40 cm was 
found after adjustment of spherical power, as well as the cylinder axis and power, by ± 0.25 D in 1° increments. 
Biometry measurements obtained using a ZEISS IOLMaster 500 (Carl Zeiss AG; Heidenheim, Germany) were 
reviewed and the ‘prediction error’, which is the predicted target refraction before surgery, was recorded. IOL 
calculations were always performed with the SRK/T formula using an A-constant of 116.9, which is the manu-
facturer’s recommendation for retropupillary fixation. This constant was used in the laser interferometry biom-
etry mode. Finally, endothelial cell count (ECC) performed automatically using specular microscopy (CellChek 
XL, Konan Medical USA Inc.; Irvine, CA, USA) was analyzed.
Surgical technique. A 25-gauge pars plana vitrectomy was performed (CONSTELLATION Vision System, 
Alcon; Fort Worth, TX, USA) for each patient. After the core vitrectomy and peripheral shaving to free the dis-
located IOL from the vitreous, the anterior chamber was filled with dispersive viscoelastics (VISCOAT, Alcon; 
Fort Worth, TX, USA), and the dislocated IOL complex was lifted up into the anterior chamber. Then, a con-
junctival incision was made from the 11 o’clock position to the 1 o’clock position using spring scissors. A 5.5 mm 
scleral flap was created using a crescent blade and a sclerocorneal incision was made using a steel keratome. The 
dislocated IOL was gently removed through the scleral tunnel. Two paracentesis incisions were made at the 2 
o’clock and 10 o’clock positions using a sharp blade, and the R-IOL (ARTISAN Aphakia model 205, OPHTEC 
BV; Groningen, Netherlands) was prepared for implantation. After filling the anterior chamber with viscoelastic 
material, the R-IOL was inserted through the previously formed scleral tunnel using ARTISAN forceps (OPH-
TEC BV; Groningen, Netherlands). The claws of the R-IOL were fixated at the 3 o’clock and 9 o’clock positions of 
the posterior iris using an enclavation needle (OPHTEC BV; Groningen, Netherlands). After closing the scleral 
tunnel incision using 10-0 nylon sutures, the remaining viscoelastic material was removed by automatic irriga-
tion and aspiration. The superior conjunctival incision was closed using 7-0 vicryl sutures. Figure 1 presents a 
detailed description of the surgical technique.
Postoperative examination. All postoperative data (uncorrected VA, BCVA, IOP, refractive errors, and 
ECC) were acquired at 1, 6, 12, and 24 months postoperatively. The SE outcome after surgery was described 
as the ‘postoperative refraction’. If there were any missing values in the postoperative data, the subjects were 
excluded from the analysis. Postoperative complications and corresponding treatments were documented for 
each case.
Statistical analyses. All statistical analyses were performed using Statistical package for the social sciences 
(SPSS/IBM Corporation; Chicago, IL, USA) version 23.0 software for Windows. The Shapiro–Wilk test was used 
to examine normality. A repeated measures analysis of variance (RM-ANOVA) with a post-hoc Fisher’s least 
significant difference (LSD) test was performed to analyze the differences in variables between multiple time-
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points. A paired t-test was used to compare two time-points. P values < 0.05 were considered to be statistically 
significant. Data are presented as the mean ± standard deviation, unless otherwise noted.
Results
Preoperative baseline characteristics. Among the 134 patients who underwent R-IOL implantation 
surgery, 29 patients who underwent R-IOL implantation for other causes (aphakia correction, n = 12; posterior 
capsular rupture or zonular dialysis during cataract surgery, n = 17) were excluded. Additionally, seven patients 
were excluded due to loss of follow-up within 24 months postoperatively. Therefore, a total of 103 eyes of 98 
patients that met the inclusion criteria were included in the present study.
Table 1 summarizes the preoperative baseline characteristics of patients enrolled in the study. The mean 
age of the study population was 60.9 ± 12.3 years (range, 18–88 years). The average follow-up duration was 
38.2 ± 6.2 months (range, 24–61 months) and the study population was predominantly comprised of men (90.8%). 
Preoperatively, the mean uncorrected VA was 0.97 ± 0.75 and the mean BCVA was 0.34 ± 0.58 on the logarithm of 
the minimum angle of resolution (logMAR) scale. The preoperative SE was + 4.96 ± 5.99 diopters (D) (range, − 19 
to + 17.75 D), and corneal astigmatism was + 1.12 ± 0.82 D (range, 0 to + 4.88 D). The mean axial length was 
25.1 ± 2.3 mm (range, 21.69–34.85 mm). The average IOP was 17.0 ± 7.7 mmHg and the endothelial cell density 
was 2164.1 ± 686.2 cells/mm2. We speculated that IOL dislocation was caused by zonular weakness in 94 eyes 
(91.3%), which included six eyes with a history of pseudoexfoliation, four eyes had damage to trauma, 24 eyes 
(23.3%) exhibited high myopia (axial length ≥ 26.5 mm), eight eyes (7.8%) had previously undergone vitreoretinal 
surgery (e.g., retinal detachment, phakic subluxation, and endophthalmitis), and two eyes (1.9%) had previously 
Figure 1.  Intraoperative photographs showing the surgical procedures for retropupillary iris claw intraocular 
lens (R-IOL) implantation. An 80-year-old male patient underwent R-IOL implantation in the left eye for the 
treatment of intraocular lens (IOL) dislocation under local anesthesia. A 25-gauge trans pars plana vitrectomy 
was performed. After performing the core vitrectomy and peripheral shaving, (A) a 5.5 mm scleral flap was 
made using a round blade under the conjunctival flap. A scleral tunnel incision was made using a steel keratome. 
After grasping the posteriorly dislocated capsular bag-IOL complex using a 25-gauge vitrectomy probe, the 
dislocated capsular bag-IOL complex was translocated into the anterior chamber and gently removed through 
the scleral tunnel using IOL forceps. (B) Two paracentesis incisions were made at the 2 o’clock and 10 o’clock 
positions using a sharp blade. The horizontal plane indicating the IOL haptic enclavation sites was marked using 
a marking pen. Viscoelastic material was injected into the anterior chamber through the scleral incision site. (C) 
The R-IOL was prepared for implantation and inserted into the anterior chamber through the previously formed 
scleral tunnel using ARTISAN forceps and was rotated. The haptics of the R-IOL were fixated at the 3 o’clock and 
9 o’clock positions of the iris using an enclavation needle. The remaining viscoelastic material was removed, and 
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received intravitreal injections (e.g., for diabetic retinopathy and retinal vein occlusion). In-the-bag IOL disloca-
tions were noted in 88 eyes (85.4%), whereas out-of-the-bag IOL dislocations were observed in 15 eyes (14.6%). 
Among the latter 15 eyes, dislocation of previous SF-IOLs was noted in nine cases (8.7%).
Visual acuity. The changes in vision before and after the R-IOL implantation surgery are shown in Fig. 2A. 
The mean uncorrected VA values 1, 6, 12, and 24 months postoperatively were 0.28 ± 0.44, 0.22 ± 0.46, 0.19 ± 0.45, 
and 0.22 ± 0.46 logMAR, respectively. The uncorrected VA one month postoperatively showed significant 
improvement (P < 0.001; RM-ANOVA with the Fisher’s LSD method) when compared with the preoperative 
uncorrected VA (0.97 ± 0.75 logMAR); it was similar to the preoperative BCVA (0.34 ± 0.58 logMAR, P = 0.99). 
The improvement in VA at one month postoperatively did not change significantly during the follow-up period 
(all P values < 0.05). The mean postoperative BCVA at one month after surgery (0.20 ± 0.29 logMAR) was simi-
lar to the uncorrected VA measured at the same time point (P = 0.91; paired t-test); this indicated a significant 
improvement when compared with the preoperative BCVA (P = 0.013; paired t-test).
Intraocular pressure. Figure 2B shows the change in IOP before and after R-IOL surgery. The mean IOP 
values 1, 6, 12, and 24 months after the operation were 14.7 ± 4.9, 14.3 ± 4.2, 14.0 ± 3.5, and 14.1 ± 3.3 mmHg, 
respectively. The IOP was significantly decreased one month after the surgery (mean difference, − 2.3 mmHg, 
P = 0.008) when compared with the preoperative IOP (17.0 ± 7.7 mmHg); there were no additional significant 
changes during the follow-up period (P values > 0.05; RM-ANOVA with Fisher’s LSD method).
Refractive error. The changes in SE before and after R-IOL surgery are presented in Fig. 2C. The mean PR 
values at 1, 6, 12, and 24 months were − 0.41 ± 1.26, − 0.18 ± 2.00, − 0.40 ± 1.29, and − 0.68 ± 1.37 D, respectively. 
When compared to the preoperative SE (+ 4.96 ± 5.99 D), a significant change was noted only at one month post-
operatively (P < 0.001; RM-ANOVA with Fisher’s LSD method). There was no significant difference between the 
mean prediction error (− 0.56 ± 0.98 D) and the 1-month postoperative refraction (P = 0.21; paired t-test). The 
1-month postoperative refraction was within ± 0.5 D, with prediction error observed in 74 eyes (71.8%). There 
were no additional significant changes in postoperative refraction between one month and 24  months after 
surgery (all P values > 0.05; RM-ANOVA with Fisher’s LSD method). A slight increase in the mean cornea astig-
matism was observed at the end of the follow-up period (1.12 ± 0.83 to 1.65 ± 1.23 D, P < 0.001; paired t-test). 
According to the slit lamp examination results, there was no apparent IOL tilt or decentration in any patients 
from our case series.
Endothelial cell count. The changes in endothelial cell density are shown in Fig. 2D. The mean ECC values 
1, 6, 12, and 24 months after the operation were 1676.8 ± 861.7, 1703.7 ± 915.3, 1740.3 ± 907.5, and 1637.8 ± 870.0 
cells/mm2, respectively. A RM-ANOVA showed an overall decline in ECC over time (P = 0.021). A significant 
Table 1.  Baseline characteristics of the patients who underwent retropupillary iris claw intraocular lens (IOL) 
implantation surgery with pars plana vitrectomy for the treatment of an IOL dislocation. logMAR, logarithm of 
the minimum angle of resolution. Values are expressed as means ± standard deviations, except where indicated 
as number (percentage) of subjects.
Total number of patients/ eyes 98/ 103
Age (years) 60.9 ± 12.3
Men/Women 89 (90.8)/9 (9.2)
Mean follow-up duration (months) 38.2 ± 6.2
Preoperative measurements
Uncorrected visual acuity (logMAR) 0.97 ± 0.75
Best-corrected visual acuity (logMAR) 0.34 ± 0.58
Spherical equivalent (diopter) 4.96 ± 5.99
Corneal astigmatism (diopter) 1.12 ± 0.82
Axial length (mm) 25.1 ± 2.3
Intraocular pressure (mmHg) 17.0 ± 7.7
Endothelial cell count (/mm2) 2164.1 ± 686.2
Speculated cause of IOL dislocation
Zonular weakness 94 (91.3)
High myopia (axial length ≥ 26.5 mm) 24 (23.3)
Previous vitreoretinal surgery 8 (7.8)
A history of pseudoexfoliation 6 (6.1)
Post-traumatic 4 (4.0)
Previous intravitreal injections 2 (1.9)
Unknown cause 50 (48.5)
Dislocation of scleral-fixated IOLs 9 (8.7)
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reduction in ECC was observed, but only for the period from before the surgery to one month after the surgery 
(− 16.6%, P = 0.027; Fisher’s LSD method).
Postoperative complications. Complications that developed after the R-IOL implantation surgery are 
summarized in Table 2. A mild degree of iris atrophy or a focal defect at the enclavation site was noted in 12 
eyes (11.7%). Eight eyes (7.8%) had transient IOP elevations. Of these eight eyes, IOP was normalized in six 
eyes after instillation of anti-glaucoma eye drops for one week. In one patient, IOP elevation was normalized six 
months after instillation of dorzolamide-timolol and latanoprost. Delayed IOP elevation three months after the 
operation was noted in another patient who had a history of chronic angle closure and required treatment with 
dorzolamide-timolol, latanoprost, and oral acetazolamide for one month.
Figure 2.  Changes in (A) visual acuity, (B) intraocular pressure, (C) spherical equivalent, and (D) endothelial 
cell count before and after retropupillary iris claw intraocular lens implantation for the treatment of intraocular 
lens dislocation. LogMAR, logarithm of the minimum angle of resolution; Pre, preoperative; POD, postoperative 
days; M, month; BC, best-corrected; UC, uncorrected; D, diopter; PE, prediction error. Repeated measures 
analysis of variance with post-hoc Fisher’s LSD test for statistical analysis was performed (*P < 0.05, †P < 0.01, 
‡P < 0.001). The small black dots represent mean data points and error bars represent standard deviations.
Table 2.  Postoperative complications of eyes that underwent retropupillary iris claw intraocular lens (IOL) 
implantation surgery combined with pars plana vitrectomy for the treatment of an IOL dislocation.
Postoperative complications N (%)
None 71 (68.9)
Iris atrophy/ focal defect 12 (11.7)
Transient elevation of intraocular pressure 8 (7.8)
Disenclavation 10 (9.7)
Cystoid macular edema 4 (3.9)
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R-IOL disenclavations were encountered in 10 eyes (9.7%). Disenclavation of the R-IOL occurred significantly 
more frequently in eyes with iris atrophy (five eyes [41.7%]) than in those without it (five eyes [5.5%]) (P = 0.002; 
Fisher’s exact test). The R-IOL disenclavations occurred shortly after the surgery in three cases; in two cases, the 
R-IOL disenclavation occurred three months postoperatively, and in one case, it occurred one week postopera-
tively. Patients with a R-IOL disenclavation required simple re-fixation using enclavation needles. The R-IOLs 
were stable after the re-fixation and did not require additional manipulation thereafter. There were no significant 
changes in BCVA, refractive errors, IOP, or ECC before and after R-IOL re-enclavation.
In addition, four patients (3.9%) had cystoid macular edema (CME). The incidence of CME was significantly 
higher in eyes that had previous re-enclavation (two eyes [20%]) than in those that did not (two eyes [2.2%]) 
(P = 0.046; Fisher’s exact test). CME occurred within six months after the operation in three cases. These cases 
of early-onset CME were treated with an intravitreal injection of bevacizumab (1.25 mg) in addition to topical 
nonsteroidal anti-inflammatory drugs. One month after the injection, the CMEs were completely resolved in 
all cases. At 1-year follow-up, the three patients with early-onset CME had a BCVA that was maintained at 0.1 
logMAR, without any further recurrence of CME. Chronic CME recurrence was observed 12 months postop-
eratively in only one patient who had underlying diabetic retinopathy.
Discussion
Herein, we investigated the safety and efficacy of primary R-IOL implantation for correcting an IOL dislocation. 
R-IOL implantation combined with IOL removal and pars plana vitrectomy provided significant improvements 
in uncorrected VA (average, − 0.69 logMAR) at one month postoperatively as compared to the preoperative 
values. The VA improvement after R-IOL implantation for an IOL dislocation was well-sustained during the 
24 months after the surgery.
Despite concerns of IOP elevation, IOP was not elevated in most cases in our study. In fact, the postopera-
tive mean IOP was significantly lower than the preoperative IOP at the 1-month follow-up postoperatively and 
remained stable thereafter. In agreement with our results, previous studies demonstrated that the mean IOP at 
the time of last follow-up after R-IOL implantation was significantly lower  than19 or similar to the preoperative 
 IOP16,17. Furthermore, six of the eight eyes that experienced IOP elevation required just a week of treatment with 
IOP lowering agents, indicating that the IOP elevation may be due to post-vitrectomy inflammation rather than 
the R-IOL itself. Baykara et al. showed that the anatomic characteristics of the anterior segment are preserved 
after R-IOL  implantation20. This indicates that R-IOL does not induce angle closure or pupillary block under 
normal circumstances. In addition, there were no cases of peripheral anterior synechiae even 24 months after 
the surgery, which also indicates that there is a low risk of chronic angle closure after R-IOL implantation.
There was no significant difference between the prediction error and postoperative refraction of the implanted 
IOL. Subsequently, the patients had very satisfactory visual quality as none of them who underwent this surgery 
had any postoperative discomfort affecting visual quality. Considerable SE error and, more commonly, IOL tilt 
that affect visual quality have been observed with SF-IOLs in previous  studies14,21–23. These complications result 
in higher-order aberrations and a deterioration of visual  quality24. In contrast, R-IOL implantation may result in 
small SE variations (− 0.50 to − 0.94 D) but, it has a low risk of inducing IOL  tilt12,17, as new needle sclerotomies 
would not be required for R-IOL. The mean surgically induced astigmatism after a 5.5 mm scleral incision for 
R-IOL implantation has been shown to be as subtle as + 0.65 D at 171°25. However, refraction changes have been 
observed due to R-IOL shift, depending on the positioning of the  head26. Further studies comparing the IOL tilt 
and SE error between eyes that underwent R-IOL implantation and eyes that underwent scleral IOL fixation are 
required to make definite conclusions.
R-IOL fixation resulted in a 16.6% decline in ECCs at the 1-month follow-up postoperatively. However, 
there was no further ECC reduction until 24 months after the surgery. Furthermore, no patient developed bul-
lous keratopathy postoperatively. In a recent randomized clinical trial that studied cases with IOL dislocations 
for six months, an average ECC loss of 10% was observed in patients who underwent IOL replacement with 
R-IOL, whereas a 3% ECC decompensation was observed in the IOL repositioning  group13. However, in other 
studies, R-IOL implantation for correcting aphakia did not significantly decrease ECC, even in patients who 
had undergone penetrating keratoplasty for bullous  keratopathy27–29 Recently, the simultaneous performance 
of R-IOL implantation and Descemet endothelial keratoplasty has been proposed as a safe technique to treat 
aphakia with corneal  decompensation30,31. No significant difference in ECC between IC-IOL (anteropupillary) 
and in-the-bag IOL has been  reported32. In addition, no significant changes in ECC have been observed in either 
anterior or posterior iris-claw implantation procedures within five years of follow-up14. Stürmer argues that the 
ECC decline might be what one would expect after surgical IOL exchange and not necessarily from the use of 
R-IOL33. We believe that IOL repositioning and aphakia correction using the R-IOL would result in a smaller risk 
of endothelial injury because nothing is removed from the intraocular space. Additionally, IOL replacement itself 
presents a risk for endothelial decompensation since the maneuvers related to the removal of the dislocated IOL 
through the scleral tunnel may cause some trauma to the corneal endothelium. Furthermore, our study shows 
that the ECC decline did not significantly progress after one month postoperatively, which may signify that the 
ECC decline was primarily due to surgical factors related to IOL removal rather than problems of R-IOL itself. 
The accuracy of ECC could be influenced by variations in cell area and image clarity, as we used an automated 
measurement technique.
Previous studies have reported high postoperative complication rates related with scleral-fixation of IOLs. 
Vote et al. reported that 30 of the 61 (49%) SF-IOL eyes required two or more procedures to reverse significant 
peri- or postoperative complications. The main indication, which accounted for 57% cases requiring reoperations, 
was caused by breakage of the polypropylene  suture34. In a study performed in an Asian population, a postopera-
tive complication rate of 24.0% (25 of 104 eyes), mostly suture-related, was reported for SF-IOLs35. Although 
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our study group has previously shown that suture-related complication rates decrease when simultaneous IOL 
rescue with suture-less intrascleral tunnel fixation is performed, this technique is limited in that it can only be 
used in cases with 3-piece IOL  dislocation36.
In our study, 9.7% of the eyes required additional procedures for the correction of partially disenclavated 
R-IOLs during the 2-year follow-up period. Previously reported disenclavation rates of R-IOL have varied 
between studies. Similar to our results, a 6.6% disenclavation rate of 122 eyes was reported over 7.5  months17, 
whereas Gonnermann et al. reported a higher disenclavation rate (14% of 137 R-IOL eyes) over 6.7  months19. 
In other studies of R-IOL eyes, disenclavation has been observed at a lower rate; for example, one reported 
disenclavation in 3/320 (0.9%)  eyes12 and another reported 2/93 (2.1%) eyes being  affected14 during a 5-year 
follow-up period. Although there are limitations that prevent direct comparisons between previous reports, 
the disenclavation rates of R-IOL (0.9–14%) seem to be relatively lower than the dislocation rates of SF-IOL 
(7.9–25.9%)3,34,37. Therefore, a long-term enclavation state of R-IOL might be more stable or sustainable than a 
conventional scleral fixation state. In our study, the three cases of early disenclavation may indicate insufficient 
tissue enclavation during the first operation. The difficulty associated with visualization of the posterior surface 
of the iris during surgery hampers the assessment of the amount of enclaved iris tissue. Simple R-IOL re-fixation 
using an enclavation needle was sufficient to correct all cases of R-IOL disenclavation. Since complete vitrectomy 
was performed previously to remove the dislocated IOL, there was no need for additional vitrectomies.
Since a previous study on iris-sutured IOLs reported severe inflammation immediately after the  operation38, 
questions have been raised regarding the risk of postoperative inflammation of R-IOL, because it is a surgery 
that requires iris manipulation. Madhivanan et al. reported that postoperative iritis was more common in R-IOL 
than in SF-IOL15. However, there was no significant difference between the two in other comparative  studies3,14. 
In our study, no patient developed significant anterior or posterior inflammation after R-IOL implantation. The 
reason for the low incidence of inflammation after R-IOL implantation may be due to the difference in the IOL 
material and the method used to fixate the IOL on the iris. While iris-sutured IOLs are primarily acrylic and 
require sutures that can injure the blood-aqueous barrier at the endothelium of the iris vessels, R-IOLs (Artisan® 
Aphakia model 205, Ophtec, Groningen, Netherlands) are suture-less and are composed of polymethyl meth-
acrylate, which induces lesser leukocytic chemotaxis and inflammation than acrylic  IOLs39. Therefore, R-IOLs 
may be safer in terms of inflammation than iris-sutured IOLs.
Although the incidence of postoperative CME was low (3.9%) in this study, Gonnermann et al. reported a 
CME incidence rate of 8.7% (average follow-up duration, 6.7 months). The inclusion of many cases with pos-
sible uveal pathologies, such as previous ocular trauma (37.5%), intracapsular cataract extraction (28.1%), and 
uveitis (6.3%), may have affected the study results of Gonnermann et al.19. In addition, they did not perform 
total vitrectomy for all patients, which also may increase the risk of CME due to vitreomacular  traction19,40. 
Recently, a 4.9% incidence of CME was reported for 122 eyes over a 7.5-month follow-up period, including cases 
in which CME was present  preoperatively17. In contrast, patients with uveitis were not included in our study 
population, and all included patients underwent total pars plana vitrectomy. This may explain our low incidence 
rate of postoperative CME despite a long follow-up duration. Three patients with delayed CME, at an average 
of 8 months (two cases at 6 months and one case at 12 months), did not have preoperative risk factors, such as 
diabetes, preoperative prostaglandin use, epiretinal membrane, or retinal vein  occlusion41. Additionally, they had 
no pre-existing vitreoretinal pathologies preoperatively. Surgical risk factors, such as vitreous loss, vitreomacular 
traction, and vitreous traction at incision  sites40, were precluded by total pars plana vitrectomy. Fluorescein angi-
ography showed a typical petalloid pattern in late-phase frames without signs of secondary causes of CME. We 
speculated that the three cases of CME were of delayed Irvine-Gass syndrome, which were successfully treated 
with an intravitreal injection of bevacizumab (1.25 mg)42–44 and topical nonsteroidal anti-inflammatory drugs.
Mild iris atrophy or a focal defect at the enclavation site was observed in 12 eyes (11.7%). These patients did 
not experience related uncomfortable symptoms, such as photophobia, glare, or multiplopia, during the mean 
follow-up period of 28 months. However, iris atrophy appears to be associated with a higher risk of disenclava-
tion. The mechanism for iris atrophy may be ischemia or mechanical stress on the iris sphincter muscles at the 
enclavation site. Further studies are required to clarify why iris atrophy occurs after R-IOL implantation, and a 
longer follow-up duration may be needed to confirm whether cases of iris atrophy are negligible in clinical prac-
tice. Pupil ovalization occurs frequently after R-IOL implantation. Gonnermann et al. reported that it occurred in 
13.9% of the patients examined, with a mean follow-up duration of five  months19. Baykara et al. found persistent 
pupil ovalization after posterior iris claw IOL implantation in 12.7% of eyes examined, with a follow-up duration 
of nine  months20. In our study, iris ovalization was observed in 10.7% of the included eyes.
There was a higher percentage of male than female patients who underwent R-IOL implantation surgery for 
the treatment of IOL dislocation, which is consistent with previous  studies45–47. Men are more prone to ocular 
trauma that might have occurred decades ago, which can be ignored and left untreated until the time of cataract 
surgery. In addition, several causes of zonule weakness are known to be predominant in men, including intraop-
erative floppy iris syndrome associated with the use of alpha-adrenergic receptor antagonists for treating benign 
prostate  hyperplasia48 and connective tissue disorders, such as Marfan  syndrome49.
The limitations of this study include its retrospective design, the heterogeneous ophthalmologic history, 
and the absence of control groups. It was not possible to conduct a comparative analysis for this study because 
of lack of sufficient data based on other methods of IOL scleral fixation. There have, however, been a few ran-
domized trials that have reported comparable outcomes for SF-IOL and R-IOL techniques; for example, one 
study assessed 30 cases of pediatric aphakia following the removal of congenital  cataracts3 and another assessed 
85 cases with partially dislocated in-the-bag  IOL13. Further studies are therefore required to compare the results 
of primary R-IOL implantation with those of other IOL implantation methods in patients with IOL dislocation, 
with a focus on the stability of IOLs and the associated complications. In addition, more long-term outcomes 
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should be investigated in terms of postoperative chronic inflammation and ECC reduction especially in cases of 
re-enclavation after primary R-IOL implantation.
To the best of our knowledge, this is the largest study on the efficacy and safety of primary R-IOL implantation 
solely for the treatment of IOL dislocation. We report visual outcomes and complications that are comparable 
to or better than those reported for scleral-fixated IOLs. Although there is no consensus on the best surgical 
technique for the treatment of IOL dislocation, we believe that R-IOL implantation combined with pars plana 
vitrectomy and the removal of the dislocated IOL is an effective and safe surgical option for the correction of 
IOL dislocation due to various causes.
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